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Background: The association of bleeding complications after PCI and poor outcome is well established. Whether this may be secondary to changes 
in the therapies offered to pts who bleed is not well studied. We assessed discharge medications in STEMI pts undergoing primary PCI stratified by 
their bleeding status, in a large, multicenter randomized trial (HORIZONS-AMI) evaluating bivalirudin vs. UFH+GPI.
Methods: Primary PCI was performed in 3345 (93%) of 3602 randomized pts, 231 (6.9%) of whom developed in-hospital protocol-defined non-
CABG related bleeding. Medication at discharge was recorded, including antiplatelet agents, ACE-I/ARBs, statins, and b-blockers.
Results: Pts who bled were older (67 [56-76]yrs vs 605 [53-70]yrs, p<0.01), more often female (36% vs. 22%, p<0.01) and diabetic (21% vs. 16%, 
p=0.04), less often smokers (58% vs. 65%, p=0.02), and were less often randomized to bivalirudin (36% vs 51% p<0.01). Figure 1 shows medication 
at discharge in pts with vs. those without in-hospital bleeding. Pts who bled were significantly less often on statins (90.2% vs. 95.9%, p<0.01) and 
B-blockers (83.7% vs. 91.1%, p<0.01), and trended to be less often on thienopyridines (96.1% vs. 98.1%, p=0.07). Aspirin and ACE-I/ARBs were 
prescribed equally to both groups.
Conclusion: After primary PCI, pts with bleeding complications are less often discharged on statins and b-blockers. 
Witholding these well established life saving therapies from bleeding pts may partially explain their poor long-term outcome. 
